Nicole Gull, PhD, received her bachelor’s degree in biological sciences and psychology from Carnegie Mellon University. Her first position after graduating was in laboratory focused on thyroid proliferative disorders, followed by a position at a startup company where she utilized bioinformatics and computer vision software to identify novel compounds that could be used to treat psychiatric disorders. Before pursuing her doctorate, she worked as a lab manager, where she generated intestinal epithelium from inducted pluripotent stem cells in the hopes of gaining insight into the pathogenesis of inflammatory bowel cancer. During her PhD, she worked under Benjamin Berman, MD, where her project focused on identifying DNA methylation alterations resulting in changes to gene expression and DNA stability. Her studies allowed her to develop a novel bioinformatics pipeline and learn how to utilize advanced statistical methods, machine learning and bioinformatics tools to better understand the epigenetic changes underlying chemoresistance in ovarian cancer patients, differences between subtypes of esophageal cancer, and development of interstitial cystitis. She is currently a postdoctoral scientist where her work focuses on the genetics and epigenetics of ovarian cancer—utilizing whole genome sequencing to identify germline and somatic changes that contribute to disease risk, and utilizing whole genome bisulfite sequencing to identify epigenetic changes that may lead to cancer recurrence as well as underlying changes involved in early disease etiology.